GNS719 + GNS710

GNS719 + GNS710 is an experimental combination of small molecule drug candidates developed by Genoscience Pharma, primarily for the treatment of various cancers. These compounds are part of a proprietary platform of lysosomotropic agents designed to target and disrupt lysosomal function within cancer cells. The primary mechanism of action involves the inhibition of palmitoyl-protein thioesterase 1 (PPT1), an enzyme essential for lysosomal protein degradation and the regulation of autophagy. By blocking PPT1, GNS719 and GNS710 induce lysosomal membrane permeabilization and inhibit the autophagic flux that cancer cells rely on for survival under stress. This dual-drug approach or series of compounds has been evaluated in Phase 1 clinical development for solid tumors and other oncology indications, representing an effort to expand the company's oncology pipeline beyond its lead candidate, GNS561.